APA (7th ed.) Citation

Parackal, A., Ting, E., Verhoek, A., Joy, A., Sehdev, S., & Hettle, R. (2024). EE317 Cost-Effectiveness of Adjuvant Olaparib in Germline BRCA1/2-Mutated, High-Risk, Human Epidermal Growth Factor-2-Negative Early Breast Cancer: A Canadian Perspective. Value in Health, 27(6), S115. https://doi.org/10.1016/j.jval.2024.03.616

Chicago Style (17th ed.) Citation

Parackal, A., E. Ting, A. Verhoek, A. Joy, S. Sehdev, and R. Hettle. "EE317 Cost-Effectiveness of Adjuvant Olaparib in Germline BRCA1/2-Mutated, High-Risk, Human Epidermal Growth Factor-2-Negative Early Breast Cancer: A Canadian Perspective." Value in Health 27, no. 6 (2024): S115. https://doi.org/10.1016/j.jval.2024.03.616.

MLA (9th ed.) Citation

Parackal, A., et al. "EE317 Cost-Effectiveness of Adjuvant Olaparib in Germline BRCA1/2-Mutated, High-Risk, Human Epidermal Growth Factor-2-Negative Early Breast Cancer: A Canadian Perspective." Value in Health, vol. 27, no. 6, 2024, p. S115, https://doi.org/10.1016/j.jval.2024.03.616.